PDA Letter
Human Element Key to Digital Transformation

Rebecca Stauffer, PDA

A QUICK Guide To Selecting a CMO

Brittany Cloud, Eurofins Lancaster Laboratories, Inc.

IG Meetings to Address Complexity of New Products

Lee Leichter, P/L Biomedical

How to Get Your ATMP From the Lab to the Market

By: Andy Fry, Team Consulting

Viral Safety Approaches for Advanced Therapy Medicinal Products

Thomas R. Kreil, PhD, Global Pathogen Safety, Shire

WHO Should Align with ICH on PACs

Rebecca Stauffer, PDA

Quality Metrics to Impact Different Pharma Sectors

Rebecca Stauffer, PDA

Leveraging Video to Improve Operations

Colleen Walson-Billin, Amgen

Storm Surrounds Clinical Trial Data in China

Yingying Liu, ECURAC, and Siegfried Schmitt, PAREXEL

Annex 1 Showcases the Need for Clear Guidance

Geert Vandenbossche, Novartis; Marc Besson, Sanofi; Gabriele Gori, GSK Vaccines; Jette Christensen, Novo Nordisk; Gerry Morris, Eli Lilly and Company

GMP Oversight of Medicines Manufacturers in the European Union

Riccardo Luigetti, EMA, Emer Cooke, EMA, Brendan Cuddy, EMA, Sebastien Goux, European Commission, and Ian Rees, MHRA

A Line of Sight Approach for Assessing Aseptic Processing Risk: Part III

Hal Baseman, Marsha Hardiman, Walter Henkels and Mike Long, ValSource

PDA Program to Address Post-Approval Hurdles

PDA Post Approval Change: Innovation for Availability of Medicines (PAC iAM) Task Force

Four Steps to Conducting a Successful Data Integrity Audit

Crystal Mersh, Quality Executive Partners

A Line of Sight Approach for Assessing Aseptic Processing Risk: Part II

Hal Baseman, Marsha Hardiman, Walter Henkels and Mike Long, ValSource

Data Integrity and the Preapproval Inspection

John Godshalk, Biologics Consulting

A Line of Sight Approach for Assessing Aseptic Processing Risk: Part I

Hal Baseman, Marsha Hardiman, Walter Henkels and Mike Long, ValSource

Drug Shortage is a "Wicked Problem"

Anders Vinther, PhD, Sanofi Pasteur